Agios Pharmaceuticals Stock News

Upgrades Wolfe Research upgraded the previous rating for Matson Inc (NYSE:MATX) from Underperform to Peer Perform. In the third quarter, Matson showed an EPS of $6.89, compared to $6.53 from the year-

Sector ETF report for FBT

First and Only Disease-modifying Therapy for EU Patients with Rare Blood Disorder First and Only Disease-modifying Therapy for EU Patients with Rare Blood Disorder

Smart Beta ETF report for FBT

Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Holly Manning - Investor Relations Brian Goff - Chief Executive Officer Sar

– U.S. PYRUKYND® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 –

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.86% and 29.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined di

– Agios Expects a Decision on the Marketing Authorization Application by the European Commission within 67 Days of the Adoption of the Positive CHMP Opinion – – Agios Expects a Decision on the

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gainers Hempacco Co., Inc. (NASDAQ: HPCO) shares jumped 63.4% to close at $8.35 after dropping 34% on Wednesday. Hempacco's common shares began trading on the Nasdaq Tuesday. The company had planned

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split. Hempacco Co., Inc. (NASDAQ: HPCO) shares climbed 63% to $8.33 after dropping 34% on

Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) jumped 48.5% to $19.90 after Novo Nordisk announced it will acquire the company for $20 per share in cash. GigaCloud Technology Inc. (NASDAQ: GCT) sur